Maximum tolerated dose of a single uniocular intravitreal injection of AAV2-sFLT01 Time of treatment through Week 52 (referred to as the "core" study) [clinicaltrials_resource:28481576b248621c32e1d84d9bfd3417]
2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum tolerated dose of a single uniocular intravitreal injection of AAV2-sFLT01 Time of treatment through Week 52 (referred to as the "core" study) [clinicaltrials_resource:28481576b248621c32e1d84d9bfd3417]
2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
Bio2RDF identifier
28481576b248621c32e1d84d9bfd3417
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:28481576b248621c32e1d84d9bfd3417
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose of a single uniocular intravitreal injection of AAV2-sFLT01
time frame [clinicaltrials_vocabulary:time-frame]
Time of treatment through Week 52 (referred to as the "core" study)
description
2 x 10^8 vector genomes (vg) A ...... sing a fixed volume of 100 μL.
identifier
clinicaltrials_resource:28481576b248621c32e1d84d9bfd3417
title
Maximum tolerated dose of a si ...... ferred to as the "core" study)
@en
type
label
Maximum tolerated dose of a si ...... 81576b248621c32e1d84d9bfd3417]
@en